Ghost Tree Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ghost Tree Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-100,000	Closed	-$5.8M	–	75
2017 Q3	$5.8M	Buy	+100,000	New	+$10.8M	1.23%	30
2016 Q3	–	Sell	-35,000	Closed	-$4.99M	–	99
2016 Q2	$4.99M	Buy	+35,000	New	+$5.1M	1.44%	27

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ghost Tree Capital's ICPT Position: Q4 2017 in Review

Ghost Tree Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 35,000 shares — an estimated $2.03M sold.

Ghost Tree Capital first reported a position in ICPT in Q1 2014 and held it in 5 quarters. The position peaked at $7.61M in Q4 2016. 168 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

Ghost Tree Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Ghost Tree Capital sold 35,000 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $2.03M.
Ghost Tree Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
Ghost Tree Capital's Intercept Pharmaceuticals, Inc. position peaked at $7.61M in Q4 2016.
168 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on Ghost Tree Capital's 13F filing for Q4 2017, filed 14 Feb 2018.